A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Sponsor: Eli Lilly and Company
Listed as NCT01205438, this PHASE3 trial focuses on Autoimmune Disease and Connective Tissue Disease and remains completed. Sponsored by Eli Lilly and Company, it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain, Albany, United States, Amarillo, United States, Anniston, United States, Atlanta, United States, Aurora, United States, Austin, United States, Aventura, United States, Bangalore, India, Barcelona, Spain and 171 more location s